Clinical trials: Recurrent Squamous Cell Carcinoma of Neck
Head and Neck Squamous Cell Carcinoma
Study of Efficacy and Safety of LJM716 and Cetuximab in Head and Neck Squamous Cell Carcinoma Patients
To establish whether LJM716 in combination with cetuximab is safe and has beneficial effects in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma.
- Trial name
- NCT02143622
- Testing
- LJM716, cetuximab
- Sponsor
- Novartis Pharmaceuticals
Oropharyngeal Squamous Cell Carcinoma
Real-world Study of First Line Pembrolizumab- or Nivolumab-treated HPV-positive Recurrent/Metastatic Oropharyngeal Squamous Cell Carcinoma
Pembrolizumab and nivolumab (with or without chemotherapy) are used to treat head and neck cancer. The middle part of the throat (oropharynx) is a common location for head and neck cancer.
- Trial name
- NCT06771674
- Testing
- Pembrolizumab, Nivolumab
- Where
- United States
- Volunteers
- 662 people
- Sponsor
- Hookipa Biotech GmbH
Head and Neck Cancer
Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003182
- Testing
- cisplatin, gemcitabine hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Hope Cancer Institute, Inc.
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
This study is researching an experimental drug called fianlimab (also called REGN3767), combined with a medication called cemiplimab compared against cemiplimab combined with placebo (a placebo looks like a treatment but does not…
- Trial name
- NCT06769698
- Testing
- FDC fianlimab+cemiplimab, Cemiplimab
- Where
- 38 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Regeneron Pharmaceuticals
Squamous Cell Carcinoma of the Head and Neck
A Study of Nivolumab in Participants With Squamous Cell Carcinoma of the Head & Neck (SCCHN) - Patient Reported Outcomes (PRO)
The purpose of the study is to capture the utilization of nivolumab among participants with squamous cell carcinoma of the head and neck (SCCHN) since its approval, and to describe the health related quality of life (HRQoL) among…
- Trial name
- VOLUME-PRO (NCT05068609)
- Testing
- Nivolumab
- Where
- United States
- Volunteers
- 509 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Merkel Cell Carcinoma
REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies
Patients received intratumoral (IT) injections of NKTR-262 in 3-week cycles for up to 3 cycles; bempegaldesleukin with or without nivolumab was administered every 3 weeks (q3w), and treatment continued until unacceptable…
- Conditions
- Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma
- Trial name
- REVEAL (NCT03435640)
- Testing
- NKTR-262, bempegaldesleukin, nivolumab
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Nektar Therapeutics
Squamous Cell Carcinoma of the Head and Neck
Study of Dalantercept in Patients With Squamous Cell Carcinoma of the Head and Neck
Dalantercept, a soluble form of the activin receptor-like kinase-1 protein, is being studied in patients with squamous cell carcinoma of the head and neck (SCCHN).
- Trial name
- NCT01458392
- Testing
- Dalantercept
- Where
- 8 sites in United States
- Volunteers
- 46 people
- Sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC)
A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors
This clinical trial is evaluating a drug called MDSY-2140 in participants with hematologic malignancies and advanced solid tumors.
- Conditions
- Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC), Gastric Cancer Adenocarcinoma Metastatic, Ovarian Cancer Metastatic
- Trial name
- NCT07899632
- Testing
- MDSY-1240
- Volunteers
- 75 people
- Sponsor
- Medsyn Biopharma, LLC
Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma
An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors
Open-label study using ASP-1929 photoimmunotherapy in combination with anti-PD1 therapy in patients with recurrent or metastatic head and neck and squamous cell cancer or advanced or metastatic cutaneous squamous cell carcinoma.
- Conditions
- Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma, Locally Advanced Cutaneous Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma
- Trial name
- NCT04305795
- Testing
- 200 mg Pembrolizumab, 350 mg Cemiplimab, ASP-1929 PIT
- Where
- 7 sites in United States
- Volunteers
- 23 people
- Sponsor
- Rakuten Medical, Inc.
Metastatic Head-and-neck Squamous-cell Carcinoma
Study for Treatment of Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Skin
This phase 2 study is designed to evaluate the safety and activity of TH-4000, a hypoxia-activated prodrug in participants with recurrent or metastatic squamous cell carcinoma of the head and neck or skin.
- Trial name
- NCT02449681
- Testing
- TH-4000 (Tarloxotinib)
- Where
- 10 sites in United States, Australia
- Volunteers
- 30 people
- Sponsor
- Rain Oncology Inc
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Enoblituzumab Plus MGA012 or MGD013 in Squamous Cell Carcinoma of the Head and Neck
This is an open-label study designed to evaluate safety and efficacy of enoblituzumab in combination with MGA012 or MGD013 in first-line treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and…
- Trial name
- NCT04129320
- Testing
- enoblituzumab, MGA012, MGD013
- Sponsor
- MacroGenics
Head and Neck Squamous Cell Carcinoma
A Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
This is a phase 3 study. All subjects arerecurrent or metastatic head and neck squamous Cell Carcinoma (R/M HNSCC), Eastern Cooperative Oncology Group (ECOG) performance status 0-1.
- Trial name
- NCT06601335
- Testing
- AK117 in combination with AK112
- Where
- 2 sites in China
- Volunteers
- 510 people
- Sponsor
- Akeso
Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer
Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic
This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6.
- Conditions
- Head & Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer
- Trial name
- NCT07807345
- Testing
- STRO-006, Pembrolizumab
- Where
- 6 sites in United States
- Volunteers
- 285 people
- Sponsor
- Sutro Biopharma, Inc.
Pancreatic Ductal Adenocarcinoma, Colorectal Cancer
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
This study was conducted to advance new treatment for patients with metastatic or locally advanced cancers expressing Neurotensin receptor 1 (NTSR1).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Gastric Cancer, Squamous Cell Carcinoma of the Head and Neck
- Trial name
- NCT03525392
- Testing
- 177Lu-3BP-227 (also called 177Lu-IPN01087)
- Where
- 8 sites in United States, Belgium and 3 more
- Volunteers
- 14 people
- Sponsor
- Ipsen
Head and Neck Squamous Cell Carcinoma
Safety and Efficacy of SCT-I10A in Head and Neck Squamous Cell Carcinoma
The objective of this study is to evaluate the efficacy and safety of SCT-I10A for Recurrent/ Metastatic Head and Neck Squamous cell Carcinoma who progressed on or after platinum-based chemotherapy
- Trial name
- NCT04146181
- Testing
- PD-1
- Where
- China
- Volunteers
- 103 people
- Sponsor
- Sinocelltech Ltd.
Solid Tumor, Adult, Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B395, an allogeneic logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), non-small cell lung cancer (NSCLC), head and neck squamous cell…
- Conditions
- Solid Tumor, Adult, Colorectal Cancer, Non-Small Cell Lung, NSCLC (Non-small Cell Lung Cancer)
- Trial name
- DENALI-1 (NCT06682793)
- Testing
- A2B395, xT CDx with HLA-LOH assay
- Where
- 10 sites in United States
- Volunteers
- 240 people
- Sponsor
- A2 Biotherapeutics Inc.
Carcinoma of Head and/or Neck
A Phase II Clinical Study to Evaluate HLX43 in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
- Trial name
- NCT06857279
- Testing
- HLX43 DOSE 1, HLX43 DOSE 2, HLX43 DOSE 3
- Where
- 2 sites in China
- Volunteers
- 167 people
- Sponsor
- Shanghai Henlius Biotech
Advanced Solid Tumor, Non-small Cell Lung Cancer
Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1
This will be a Phase 1 Open-label, dose escalation and expansion study of MT-6402 (an Engineered Toxin Body (ETB)) in subjects with advanced solid cancer that expresses PD-L1
- Conditions
- Advanced Solid Tumor, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT04795713
- Testing
- MT-6402
- Where
- 16 sites in United States
- Volunteers
- 64 people
- Sponsor
- Molecular Templates, Inc.
Incurable Metastatic Colorectal Carcinoma, Incurable Progressive, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
Phase 1 and 2 Study of PX-866 and Cetuximab
The purpose of this Phase 1/2 open-label study is to determine the safety and efficacy of a cetuximab and PX-866 combination treatment.
- Trial name
- NCT01252628
- Testing
- PX-866 (SCCHN), Cetuximab (SCCHN), PX-866 (CRC)
- Where
- 40 sites in United States, Canada
- Volunteers
- 178 people
- Sponsor
- Cascadian Therapeutics Inc.
Head and Neck Neoplasms
A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell…
- Trial name
- NCT01087970
- Testing
- Pemetrexed, Cetuximab, Carboplatin
- Where
- 21 sites in United States
- Volunteers
- 69 people
- Sponsor
- Eli Lilly and Company